EP300 and neoplasm: In B-lymphoma cells, mutation or knockdown of CREBBP or EP300 decreases H3K27 acetylation, downregulates FBXW7 expression, and activates the NOTCH pathway and downstream CCL2/CSF1 expression, leading to tumor cell proliferation and tumor-associated macrophage (TAM) polarization toward the M2 phenotype.